Phase II Study Of The Impact Of AZD4017, A Selective 11bHSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia

Trial Profile

Phase II Study Of The Impact Of AZD4017, A Selective 11bHSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs AZD 4017 (Primary)
  • Indications Metabolic bone diseases
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2015 Accrual to date is 8%, according to United Kingdom Clinical Research Network record.
    • 28 May 2015 Status changed from not yet recruiting to recruiting as per United Kingdom Clinical Research Network.
    • 16 May 2015 Status changed from suspended to recruiting, as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top